Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.33 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.33 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.33 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16534878 | 0.82 | MEN1 (0.36) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16535307 | 0.79 | PDE4A (0.38) | PDE4APDE4BPDE4CPDE4DKDM5A | |
| SCHEMBL16535509 | 0.79 | KDM5A (0.32) | KDM5A | |
| SCHEMBL16535079 | 0.78 | KDM4E (0.32) | EGLN2 | |
| SCHEMBL16534729 | 0.78 | EED (0.30) | — | |
| SCHEMBL16534823 | 0.77 | KDM5A (0.34) | KDM5A | |
| SCHEMBL16535286 | 0.77 | MEN1 (0.40) | — | |
| SCHEMBL16534881 | 0.77 | CYP2C19 (0.45) | KDM5A | |
| SCHEMBL16534745 | 0.76 | MAP4K1 (0.33) | — | |
| SCHEMBL16534874 | 0.76 | PARP1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041474-B1 | ANTIPROLIFERATIVE COMPOUNDS | GENENTECH INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-9505767-B2 | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505767-B2 | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505767-B2 | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors | GENENTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-3041474-A1 | ANTIPROLIFERATIVE COMPOUNDS | Genentech, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015035062-A1 | ANTIPROLIFERATIVE COMPOUNDS | GENENTECH, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035062-A1 | ANTIPROLIFERATIVE COMPOUNDS | GENENTECH, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065522-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM5A, KDM5B, KDM5C | PDE4A 679/4885PDE4B 411/4885PDE4C 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.